51 In randomized clinical trials in postmenopausal women with osteoporosis, raloxifene reduced the risk of newly diagnosed estrogen receptor positive invasive breast cancer by 76 during a median of 40 months of treatment <a href=https://stromectol.homes/>stromectol</a>
